Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 2,690 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline solution Clear all

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 43
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more

Conditions: Coronary Artery Disease
Interventions: Methylnaltrexone, Placebo, Morphine, Ticagrelor; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Septic Shock, Hypotension, Tachycardia
Interventions: Esmolol, Saline; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo; Biological
Lead sponsor: Kara Chew; Other
Eligibility: 40 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Multiple Myeloma
Interventions: Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Infections, Ankle Arthritis
Interventions: Intraosseous Vancomycin Injection, Intravenous Vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Dociparstat, Control; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Orange, California • Westwood, Kansas • Louisville, Kentucky + 11 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual; Other · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 85 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more

Conditions: Abortion, Dilation and Evacuation, Hemorrhage, Prophylactic Tranexamic Acid Use, Blood Loss
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: San Diego, California • Chicago, Illinois

Conditions: COVID-19
Interventions: Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine; Drug · Biological
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Davis, California • Irvine, California + 30 more

Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Radical Prostatectomy; Device · Procedure
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 26
States / cities: Chandler, Arizona • Mesa, Arizona • Los Angeles, California + 22 more

Conditions: Migraine Headache
Interventions: Auricular Acupuncture, Ketorolac 0.5mg/kg, max 30mg, Metoclopramide 0.1 mg/kg, max 10mg, Diphenhydramine 1mg/kg, max 50mg, Normal saline fluid bolus 20mL/kg, max 1000mL; Other · Drug
Lead sponsor: University of Louisville; Other
Eligibility: 8 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: PRP, Sexual Function Disturbances, Genitourinary Syndrome of Menopause, Postmenopausal Symptoms, Vaginal Atrophy
Interventions: Injection of platelet-rich plasma, Injection of saline; Procedure
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Candidiasis
Interventions: fluconazole, placebo; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 2 Days to 5 Days
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 33
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more

Conditions: Opioid Use Disorder, Back Pain, Stress
Interventions: Placebo, Oxycodone, Naloxone; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atrial Fibrillation
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Joseph Mathew, M.D.; Other
Eligibility: 50 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Shock, Septic
Interventions: 25% Albumin, Placebo; Drug
Lead sponsor: Alexander Flannery, 859-323-4011; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Plaque Psoriasis.
Interventions: Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36; Drug
Lead sponsor: ASIS Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Westminster, California

Conditions: Chest Pain, Acute Coronary Syndrome
Interventions: Dexmedetomidine, Normal Saline, Intranasal cocaine; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: UVL1000 Treatment Station, Normal Saline 0.9% Infusion Solution Bag, Peripheral Catheterization; Device · Drug
Lead sponsor: John W. Reeves, MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Hip Fractures, Surgical Blood Loss
Interventions: Tranexamic Acid, Placebo; Drug · Other
Lead sponsor: Good Samaritan Regional Medical Center, Oregon; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Restless Legs Syndrome
Interventions: equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml, Normal saline - 1ml; Drug
Lead sponsor: Lowcountry Infectious Diseases; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Surgical Blood Loss
Interventions: Saline-coupled Bipolar Sealer, Unipolar electrocautery; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Syosset, New York

Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions: TTAX01, Standard Care; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: San Francisco, California • Sylmar, California • Miami, Florida + 13 more

Search by objective public record fields.

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

Esmolol to Treat the Hemodynamic Effects of Septic Shock

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

WATER IV Prostate Cancer

Auricular Acupuncture vs SOC in Migraine HA

PRP Injections for Genitourinary Syndrome of Menopause

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

ASIS for Enbrel in Plaque Psoriasis

Dexmedetomidine for Reversal of Cocaine's Effects on the Heart

Feasibility of Polychromatic Light Emitting Diode System to Reduce Pain

Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures

Neuroma Injections to Treat Restless Legs Syndrome - RCT

To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)